NITYR® (nitisinone) Tablets
What is NITYR?
NITYR is an FDA-approved tablet indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Designed with convenience in mind, NITYR may give patients and their caregivers one less thing to worry about.
At Cycle, we know that supporting people with rare diseases is about more than just the medicine. That’s why we created Cycle Vita, delivering individualized product support with NITYR, every step of the way.
More and more people with HT-1 and their caregivers are discovering the independence NITYR can bring to their nitisinone medicine.
NITYR product support available to you
Start your NITYR enrollment here
Download, complete and fax a PDF
The first 24hrs
Your Cycle Vita team will quickly get to work with your insurance provider to help you understand your coverage.
We will coordinate seamlessly between different parties, such as insurance companies, doctors, and pharmacists to meet your prior authorization and documentation requirements.
We will route your NITYR therapy to the appropriate specialty pharmacy and follow-up to ensure swift shipment of your medication.
Additional assistance, when required, throughout your journey
In some cases, an appeal may be needed. Where this is the case, our experienced team will work with your insurer and doctor to understand and overcome any NITYR reimbursement gaps.
A $0 co-pay is available for eligible commercially insured patients.* This program will help cover the cost of insurance co-pays for NITYR, up to the program maximum, for those who are eligible. Please contact our Access Specialists to find out more about this and other programs that may be available to you (such as Quick Start, Bridge Program etc.).
Our proactive team will remind your doctor when your NITYR prescription needs to be renewed, in a timely manner, to ensure an uninterrupted supply of your therapy.
We provide product support to help you manage every aspect of your NITYR therapeutic routine, such as clinical education and 1-to-1 administration training either at home or in-clinic.
Translation services are available on request.
What is HT-1?
Hereditary Tyrosinemia Type 1 (HT-1) is an inherited autosomal recessive genetic condition. When a person is born with tyrosinemia type 1 their body is missing the enzymes to break down the amino acid tyrosine in food. Without this enzyme, a dangerous buildup of toxic substances in the body can occur. This in turn can lead to serious liver and kidney problems, making early diagnosis and management essential.
Following a low protein diet is a key part of living with HT-1. Published medical guidelines recommend patients with HT-1 follow a low-protein diet to avoid complications associated with elevated plasma tyrosine levels. 1 However, eating properly while following a low-protein diet can be challenging.
As part of the NITYR Experience, eligible patients can utilize the Patient Nutrition Program, which provides access to a Registered Dietitian to support you in following the nutrition goals set and agreed upon by your healthcare team. Please contact our Access Specialists to find out more about this and other programs that may be available to you.
In the United States, HT-1 is primarily diagnosed at birth. Newborn screening typically involves a heel stick blood test. However, a positive screening result may not be definitive. Your healthcare provider will generally order additional blood and urine tests to confirm the diagnosis. Early testing gives the opportunity to start treating you baby as early as possible, minimizing the risk of further complications.
Remember, you’re not alone. The Cycle Vita team is here to support you for life.
*$0 co-pay for eligible commercially insured patients within specified limits and relevant terms and conditions.
Cycle Vita™ is a trademark of Cycle Pharmaceuticals in the United States. NITYR® is a registered trademark of Cycle Pharmaceuticals in the United States.
- Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, Waisbren S, Gucsavas-Calikoglu M, Wasserstein MP, Coakley K, Scott CR, Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017 Dec;19(12):1-16. doi: 10.1038/gim.2017.101
Important Safety Information and Indications
IMPORTANT SAFETY INFORMATION
Do not take NITYR if you are allergic to nitisinone or any other ingredients. Tell your healthcare provider about any health problems, and if you are pregnant or planning to become pregnant and/or breastfeeding, before starting treatment.
WARNINGS AND PRECAUTIONS
Increased levels of plasma tyrosine, eye symptoms, developmental delay and skin changes:
- Inadequate restriction of tyrosine and phenylalanine intake can result in elevations of plasma tyrosine.
- Plasma tyrosine levels above 500 micromol/L may lead to ocular signs and symptoms including corneal ulcers, corneal opacities, keratitis, conjunctivitis, eye pain, and photophobia, intellectual disability and developmental delay or painful hyperkeratotic plaques (thickening of the skin) on the soles and palms.
- Your healthcare provider should not adjust NITYR dosage in order to lower the levels of tyrosine in the blood.
- Your healthcare provider will obtain a slit-lamp examination prior to initiating NITYR treatment, regularly during treatment and may reexamine you if you develop symptoms or if your tyrosine levels are above 500 micromol/L.
Changes in blood profile
- You may develop leukopenia (reduction in the number of white blood cells, which form part of the immune system) and severe thrombocytopenia (abnormally low levels of platelets, which help the blood to clot).
- Your healthcare provider will monitor platelet and white blood cell counts, and will adjust your medication accordingly.
MOST COMMON ADVERSE REACTIONS
The most common adverse reactions (≥1%) in patients with HT-1 taking nitisinone are elevated tyrosine levels, low platelets (thrombocytopenia) or white cells in the blood (leukopenia), and complaints related to the eyes, including conjunctivitis, corneal opacity, inflammation of the cornea, eye pain and extreme sensitivity to light (photophobia), nosebleed (epistaxis), itching (pruritus), skin inflammation (exfoliative dermatitis), rash (maculopapular rash), dry skin and alopecia.
Nitisinone can interfere with the effect of other medicines. Tell your healthcare provider or pharmacist if you are taking, have recently taken or might take any other medicines.
USE IN SPECIFIC POPULATIONS:
Pregnancy: The safety of this medicine has not been studied in pregnancy. Tell your healthcare provider imediately if you become pregnant or planning to become pregnant.
Lactation: The safety of this medicine has not been studied in breastfeeding women. Tell your healthcare provider imediately if you plan on breastfeading.
Pediatric Use: The safety and effectiveness of nitisinone have been established in pediatric patients for the treatment of HT-1 in combination with dietary restriction of tyrosine and phenylalanine. Use of NITYR in pediatric patients is supported by evidence from one open-label, uncontrolled clinical study conducted with another oral formulation of nitisinone in 207 patients with HT-1 ages 0 to 22 years (median age 9 months)
Geriatric Use: Clinical studies of nitisinone did not include any subjects aged 65 and over. No clinical studies of nitisinone have been performed in geriatric patients. Your healthcare provider will adjust the dose based on your requirements.
For more detailed information, please refer to the full prescribing information at www.nityr.us/pi.
If you get any side effects, talk to your healthcare provider. This includes possible side effects not listed in this brochure. You may also report side effects directly by calling Cycle Pharmaceuticals at 1-855-831-5413 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This website is for education purposes only. It is not intended to be, and should not be used as, a substitute for medical advice.
NITYR® (nitisinone) Tablets are a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.